Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation

Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering

(2015) Yuki Iwayanagi et al.   JOURNAL OF IMMUNOLOGY

Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys

(2015) S Dudal et al.   mAbs

 De novoisolation of antibodies with pH-dependent binding properties

(2015) Pauline Bonvin et al.   mAbs

Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation

(2015) N Hironiwa et al.   mAbs

Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates

(2015) Andrew E. Nixon et al.   Frontiers in Immunology

Characterization of ASKP1240, a Fully Human Antibody Targeting Human CD40 With Potent Immunosuppressive Effects

(2014) K. Okimura et al.   AMERICAN JOURNAL OF TRANSPLANTATION

pH-dependent antigen-binding antibodies as a novel therapeutic modality

(2014) T. Igawa et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

(2014) Valérie F. Cosson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin- 18 mAb GSK1070806 in healthy and obese subjects

(2014) Prafull Mistry et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

(2014) Vaheh Oganesyan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display

(2014) Christian Schröter et al.   mAbs

Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria

(2014) Ulrike M. Reiss et al.   PEDIATRIC BLOOD & CANCER

The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups

(2014) Philip R. Cooper et al.   Frontiers in Pharmacology

Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies

(2014) Caitlin Gillis et al.   Frontiers in Immunology

Mechanistic Pharmacokinetic/Target Engagement/Pharmacodynamic (PK/TE/PD) Modeling in Deciphering Interplay Between a Monoclonal Antibody and Its Soluble Target in Cynomolgus Monkeys

(2013) Weirong Wang et al.   AAPS Journal

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

(2013) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics

(2013) Craig Giragossian et al.   CURRENT DRUG METABOLISM

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer’s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

(2013) Izuru Miyoshi et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics

(2013) Siva Charan Devanaboyina et al.   mAbs

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant

(2013) Futa Mimoto et al.   mAbs

Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo

(2013) Tomoyuki Igawa et al.   PLoS One

Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates

(2012) Karen J. Vincent et al.   Biotechnology Journal

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

(2012) Liwen Zhang et al.   International Journal of Biological Sciences

Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9

(2012) Javier Chaparro-Riggers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fc RIIb on Liver Sinusoidal Endothelium Clears Small Immune Complexes

(2012) L. P. Ganesan et al.   JOURNAL OF IMMUNOLOGY

Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

(2012) Deborah L. Mortensen et al.   mAbs

Mouse model recapitulating human Fc  receptor structural and functional diversity

(2012) P. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic antibodies: Market considerations, disease targets and bioprocessing

(2011) John G. Elvin et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Systemic Inflammation Modulates Fc Receptor Expression on Microglia during Chronic Neurodegeneration

(2011) K. Lunnon et al.   JOURNAL OF IMMUNOLOGY

Engineering the variable region of therapeutic IgG antibodies

(2011) Tomoyuki Igawa et al.   mAbs

Beyond natural antibodies: the power of in vitro display technologies

(2011) Andrew R M Bradbury et al.   NATURE BIOTECHNOLOGY

A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches

(2011) Megan L. Murtaugh et al.   PROTEIN SCIENCE

Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys

(2010) Jim J. Xiao et al.   AAPS Journal

Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study

(2010) Y Zheng et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-  Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys

(2010) R. Deng et al.   DRUG METABOLISM AND DISPOSITION

HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer

(2010) Fusanori Yotsumoto et al.   INTERNATIONAL JOURNAL OF CANCER

Neonatal Fc Receptor: From Immunity to Therapeutics

(2010) Timothy T. Kuo et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice

(2010) L. Robles-Carrillo et al.   JOURNAL OF IMMUNOLOGY

The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis

(2010) A. M. Betts et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

(2010) Tomoyuki Igawa et al.   NATURE BIOTECHNOLOGY

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

(2009) Y. A. Yeung et al.   JOURNAL OF IMMUNOLOGY

Target-mediated drug disposition model: relationships with indirect response models and application to population PK–PD analysis

(2009) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

(2009) J. C. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Studies of pH-Dependent Ligand Interactions with the Low-Density Lipoprotein Receptor†

(2008) Taichi Yamamoto et al.   BIOCHEMISTRY

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

(2008) T. MEYER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

(2008) Seung Y. Chu et al.   MOLECULAR IMMUNOLOGY

FDA Report: Eculizumab (Soliris(R)) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

(2008) A. Dmytrijuk et al.   ONCOLOGIST